SIAD: practical recommendations for diagnosis and management.

Area of Science:

• Nephrology
• Endocrinology
• Internal Medicine

Background:

• Hyponatremia is a common hospital complication, often caused by the syndrome of inappropriate antidiuresis (SIAD).
• SIAD-induced hyponatremia is linked to higher morbidity and mortality rates.
• Effective treatment is crucial for improving patient outcomes.

Purpose of the Study:

• To review current evidence-based therapies for SIAD.
• To evaluate the efficacy and limitations of fluid restriction and pharmacological interventions.
• To discuss updated management strategies for acute hyponatremia.

Main Methods:

• Review of clinical guidelines and evidence for SIAD treatments.
• Analysis of randomized controlled trials for tolvaptan efficacy.
• Discussion of therapeutic approaches including fluid restriction, vasopressin-2 receptor antagonists, and hypertonic saline.

Main Results:

• Fluid restriction, while a first-line recommendation, has limited efficacy and feasibility.
• Oral tolvaptan demonstrates clinical efficacy in SIAD, supported by robust clinical trials.
• Cost and long-term safety data are potential limitations for tolvaptan use.

Conclusions:

• Recent advances offer improved management options for SIAD-hyponatremia.
• Tolvaptan presents a viable pharmacological option, though cost and safety data require consideration.
• New recommendations emphasize bolus therapy with 3% hypertonic sodium chloride for acute hyponatremia.